Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men

Despite the substantial preclinical evidence for a positive effect of the polyphenolic compound resveratrol, human data are very scarce, and currently no clinical data addressing the potential impact on bone metabolism have been published. In the present study we addressed this issue in order to identify potential bone metabolic effects of resveratrol in human subjects. In a randomised, placebo-controlled, double-blinded and parallel-group design, 24 obese [BMI (kg/m2): 34.2 ± 0.7] non-diabetic men were randomly assigned to 500 mg resveratrol or placebo treatment three times daily for four weeks. Biomarkers of bone metabolism, inflammatory parameters and circulating hormones were measured before and after the intervention period. Plasma levels of bone-specific alkaline phosphatase increased significantly in the resveratrol group as compared to placebo [delta changes (U/l); resveratrol: 4.9 ± 0.6 vs. placebo: −1.7 ± 0.7; P